However, phosphorylation of this site is restored by oxali-Pt in a Chk2-independent manner to activate p53 and circumvent cis-Pt resistance in all tumor models, and this suggests loss of p53 phosphorylation, and not mutation, is the main driver of cis-Pt resistance in these models of ovarian cancer. This evidence concerns the gene TP53 and ovarian carcinoma.